About: Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection
Creator	Panopoulou, Maria Panagopoulos, Periklis Papazoglou, Dimitrios Penlioglou, Theano Petrakis, Vasilis Pnevmatikos, Ioannis Trypsianis, Grigorios
Source	Medline; PMC
abstract	Corona Virus Disease (CoVID-19) is an emerging public health problem rapidly spread globally. New treatment options for patients with severe symptoms and ways of reducing transmission in the community are taken into consideration. A retrospective study was conducted in the Department of Infectious Diseases of Alexandroupolis (Greece) including 16 patients with CoVID-19. They were classified into two groups, A and B. Group A received lopinavir/ritonavir as a third agent in the antiviral regimen, while group B did not. Lymphocytes were more significantly increased in patients of group A. Ferritin serum levels were also decreased significantly in these patients. Number of days needed for a first negative result of Real Time- Polymerase Chain Reaction (RT-PCR) was lower for Group A. The present study suggests that lopinavir/ritonavir may reduce the viral carriage in a shorter period of time compared with other antiviral regimens. Further studies are needed in order to evaluate the effectiveness of lopinavir/ritonavir in the treatment of patients with SARS-CoV-2 infection.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.1080/1120009x.2020.1775424
bibo:pmid	32530369
has license	no-cc
sha1sum (hex)	44ffefb264faf5a03e45887a5694fbd07831f303
schema:url	https://doi.org/10.1080/1120009x.2020.1775424
resource representing a document's title	Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection
has PubMed Central identifier	PMC7298881
has PubMed identifier	32530369
schema:publication	J Chemother
resource representing a document's body	covid:44ffefb264faf5a03e45887a5694fbd07831f303#body_text
is schema:about of	named entity 'Department' named entity 'patients' named entity 'Alexandroupolis' named entity 'SARS-CoV-2' named entity 'severe' named entity 'EFFECTIVENESS' named entity 'AGENT' named entity 'THESE' named entity 'VIRUS DISEASE' named entity 'RITONAVIR' named entity 'CORONA' covid:arg/44ffefb264faf5a03e45887a5694fbd07831f303 named entity 'antiviral' named entity 'Disease' named entity 'patients' named entity 'received' named entity 'ritonavir' named entity 'lopinavir' named entity 'Corona Virus Disease' named entity 'Greece' named entity 'SARS-CoV-2' named entity 'negative result' named entity 'fibrinogen' named entity 'non-segmented' named entity 'WHO' named entity 'ritonavir' named entity 'lopinavir/ritonavir' named entity 'CRP' named entity 'SARS-CoV-2' named entity 'ritonavir' named entity 'SPSS Inc.' named entity 'viral load' named entity 'China' named entity 'myeloid' named entity 'negative result' named entity 'lopinavir/ritonavir' named entity 'standard deviation' named entity 'lymphocytopenia' named entity 'COVID-19' named entity 'RNA viruses' named entity 'infection' named entity 'respiratory tract infections' named entity 'dimers' named entity 'infection' named entity 'HIV' named entity 'dimers' named entity 'chronic renal failure' named entity 'malaria' named entity 'SARS-CoV-2' named entity 'biochemical' named entity 'CoVID-19' named entity 'viruses' named entity 'WHO' named entity 'intubation' named entity 'Chicago' named entity 'oxygen levels' named entity 'Greece' named entity 'public health' named entity 'CoVID-19' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'lopinavir/ritonavir' named entity 'autophagy' named entity 'RT-PCR' named entity 'immunomodulatory' named entity 'MERS' named entity 'lopinavir' named entity 'antiviral' named entity 'laboratory analysis' named entity 'Severe Acute Respiratory Syndrome Coronavirus 2' named entity 'lymphocytes' named entity 'viral replication' named entity 'severe pneumonia' named entity 'ferritin' named entity 'lopinavir'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software